1. Home
  2. ANIK vs GLSI Comparison

ANIK vs GLSI Comparison

Compare ANIK & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Anika Therapeutics Inc.

ANIK

Anika Therapeutics Inc.

HOLD

Current Price

$9.45

Market Cap

142.5M

Sector

Health Care

ML Signal

HOLD

Logo Greenwich LifeSciences Inc.

GLSI

Greenwich LifeSciences Inc.

HOLD

Current Price

$13.64

Market Cap

123.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANIK
GLSI
Founded
1983
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
142.5M
123.9M
IPO Year
1993
2020

Fundamental Metrics

Financial Performance
Metric
ANIK
GLSI
Price
$9.45
$13.64
Analyst Decision
Buy
Strong Buy
Analyst Count
1
1
Target Price
$16.00
$39.00
AVG Volume (30 Days)
170.5K
342.7K
Earning Date
11-05-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$112,806,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.79
N/A
P/E Ratio
N/A
N/A
Revenue Growth
30.55
N/A
52 Week Low
$7.87
$7.78
52 Week High
$18.37
$14.47

Technical Indicators

Market Signals
Indicator
ANIK
GLSI
Relative Strength Index (RSI) 44.48 79.42
Support Level $9.36 $10.00
Resistance Level $9.82 $14.01
Average True Range (ATR) 0.21 1.18
MACD -0.02 0.45
Stochastic Oscillator 15.22 90.78

Price Performance

Historical Comparison
ANIK
GLSI

About ANIK Anika Therapeutics Inc.

Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.

About GLSI Greenwich LifeSciences Inc.

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.

Share on Social Networks: